New combo therapy aims to beat childhood lymphoma
NCT ID NCT07168980
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding the drug rituximab early and intensively to a strong chemotherapy regimen can improve outcomes for children and teens with aggressive B-cell non-Hodgkin lymphoma. About 87 participants will receive the combination therapy. The goal is to see if this approach leads to better event-free survival and overall survival compared to historical results from an earlier study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rituximab combined with chemotherapy drugs (cyclophosphamide, vincristine, cytarabine, doxorubicin, prednisone, ifosfamide, etoposide, methotrexate)
- What this could lead to
- If successful, this could offer a more effective treatment option for children with aggressive B-cell non-Hodgkin lymphoma, potentially improving long-term survival rates.
- What could go wrong
- This is a Phase 2/3 trial with only 87 participants, comparing results to past studies rather than a current control group. The intensive chemotherapy carries significant side effects, and the benefit of adding rituximab early is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE MATURE B-CELL NON-HODGKIN LYMPHOMA NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, Shanghai Municipality, 201315, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?